Of note, in MYCN-amplified NB cells (IMR32 and NGP), SETD8 pharmacological inhibition after SGSS05-NS3 treatment led to a dose-dependent reduction of p53K382me1 and H4K20me1 expression levels (Figures S5B-S5D and Figure S6A-S6B), and to a dose-dependent increase in cell death (Trypan blue positive cells) (Figure S5E and Figure S6C). This evidence concerns the gene KRAS and neuroblastoma.